Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3034% above fair value
$91.35−1.69 (-1.82%)
Close on Nov 20, 2026Market cap $10.37BP/E 26.9Yield –
Halozyme Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Halozyme Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.66B, up 41.2% year over year. For fiscal 2025 it was $1.40B, up 37.6% from the year before. Over ten years it grew 26.3% a year on average. The highest annual figure on record is $1.40B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40B | +37.6% |
| FY2024 | Dec 31, 2024 | $1.02B | +22.4% |
| FY2023 | Dec 31, 2023 | $829.25M | +25.6% |
| FY2022 | Dec 31, 2022 | $660.12M | +48.9% |
| FY2021 | Dec 31, 2021 | $443.31M | +65.7% |
| FY2020 | Dec 31, 2020 | $267.59M | +36.5% |
| FY2019 | Dec 31, 2019 | $195.99M | +29.1% |
| FY2018 | Dec 31, 2018 | $151.86M | -52.0% |
| FY2017 | Dec 31, 2017 | $316.61M | +115.8% |
| FY2016 | Dec 31, 2016 | $146.69M | +8.6% |
| FY2015 | Dec 31, 2015 | $135.06M | +79.3% |
| FY2014 | Dec 31, 2014 | $75.33M | +37.5% |
| FY2013 | Dec 31, 2013 | $54.80M | +29.5% |
| FY2012 | Dec 31, 2012 | $42.33M | -24.5% |
| FY2011 | Dec 31, 2011 | $56.09M | +311.7% |
| FY2010 | Dec 31, 2010 | $13.62M | -0.3% |
| FY2009 | Dec 31, 2009 | $13.67M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $481.00M | +47.7% |
| Q1 FY2026 | Mar 31, 2026 | $376.71M | +42.2% |
| Q4 FY2025 | Dec 31, 2025 | $451.77M | +51.6% |
| Q3 FY2025 | Sep 30, 2025 | $354.26M | +22.1% |
| Q2 FY2025 | Jun 30, 2025 | $325.72M | +40.8% |
| Q1 FY2025 | Mar 31, 2025 | $264.86M | +35.2% |
| Q4 FY2024 | Dec 31, 2024 | $298.01M | +29.5% |
| Q3 FY2024 | Sep 30, 2024 | $290.08M | +34.3% |
| Q2 FY2024 | Jun 30, 2024 | $231.35M | +4.7% |
| Q1 FY2024 | Mar 31, 2024 | $195.88M | +20.8% |
| Q4 FY2023 | Dec 31, 2023 | $230.04M | +26.7% |
| Q3 FY2023 | Sep 30, 2023 | $216.03M | +3.4% |
| Q2 FY2023 | Jun 30, 2023 | $221.04M | +45.1% |
| Q1 FY2023 | Mar 31, 2023 | $162.14M | +38.3% |
| Q4 FY2022 | Dec 31, 2022 | $181.50M | +77.9% |
| Q3 FY2022 | Sep 30, 2022 | $208.98M | +80.4% |
| Q2 FY2022 | Jun 30, 2022 | $152.37M | +11.7% |
| Q1 FY2022 | Mar 31, 2022 | $117.28M | +31.7% |
| Q4 FY2021 | Dec 31, 2021 | $102.00M | -16.2% |
| Q3 FY2021 | Sep 30, 2021 | $115.83M | +77.3% |
| Q2 FY2021 | Jun 30, 2021 | $136.46M | +147.1% |
| Q1 FY2021 | Mar 31, 2021 | $89.02M | +251.1% |
| Q4 FY2020 | Dec 31, 2020 | $121.70M | +126.8% |
| Q3 FY2020 | Sep 30, 2020 | $65.32M | +41.3% |
| Q2 FY2020 | Jun 30, 2020 | $55.22M | +41.1% |
| Q1 FY2020 | Mar 31, 2020 | $25.35M | -55.5% |
| Q4 FY2019 | Dec 31, 2019 | $53.67M | -10.9% |
| Q3 FY2019 | Sep 30, 2019 | $46.23M | +80.9% |
| Q2 FY2019 | Jun 30, 2019 | $39.15M | +11.2% |
| Q1 FY2019 | Mar 31, 2019 | $56.95M | +84.5% |
| Q4 FY2018 | Dec 31, 2018 | $60.23M | -68.2% |
| Q3 FY2018 | Sep 30, 2018 | $25.56M | -59.9% |
| Q2 FY2018 | Jun 30, 2018 | $35.20M | +4.3% |
| Q1 FY2018 | Mar 31, 2018 | $30.87M | +4.4% |
| Q4 FY2017 | Dec 31, 2017 | $189.56M | +386.0% |
| Q3 FY2017 | Sep 30, 2017 | $63.73M | +100.1% |
| Q2 FY2017 | Jun 30, 2017 | $33.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.57M | – |
| Q4 FY2016 | Dec 31, 2016 | $39.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $31.85M | – |
See a number that looks wrong?